Polymeric antitumor agents on a molecular and on a cellular level?

L Gros, H Ringsdorf, H Schupp - … Chemie International Edition …, 1981 - Wiley Online Library
“Chemistry has become a mature science, with all the advantages and handicaps of maturity:
harvest is abundant, but many people think future and adventure are to be found elsewhere…

Enzymology of the repair of free radicals-induced DNA damage

L Gros, MK Saparbaev, J Laval - Oncogene, 2002 - nature.com
A number of intrinsic and extrinsic mutagens induce structural damage in cellular DNA. These
DNA damages are cytotoxic, miscoding or both and are believed to be at the origin of cell …

Understanding, improving and using green fluorescent proteins

…, R Heim, SR Adams, AE Boyd, LA Gross… - Trends in biochemical …, 1995 - cell.com
… Boyd and L Gross, unpublished). The proposed mechanism predicts a loss of 2~ whereas
cyclization after oxidation would give a 20Da loss. Measured time constants for the oxidative …

Association of β2‐adrenergic receptor polymorphisms with severe asthma

…, Sawyer, Fitzharris, Pearce, L Gros… - Clinical & …, 2000 - Wiley Online Library
Background There is considerable interest in the role of different candidate loci in the
development of asthma. This study investigates the association between asthma severity and …

“Spontaneous” Leukemia Developing in G3H Mice Following Inoculation, In Infancy, with AK-Emkemic.

L Gross - Proceedings of the Society for Experimental …, 1951 - journals.sagepub.com
Seven of 14 C3H mice inoculated when less than 12 hours old with Ak leukemic extracts
developed leukemia at 8 to 11 months of age. 2. Four of 6 C3H mice inoculated. when less than …

[HTML][HTML] Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT

…, M Ciufolini, L Gros, M Humbert, N Castéran, L Borge… - PloS one, 2009 - journals.plos.org
Background The stem cell factor receptor, KIT, is a target for the treatment of cancer,
mastocytosis, and inflammatory diseases. Here, we characterise the in vitro and in vivo profiles of …

[PDF][PDF] Blocking antibodies targeting the CD39/CD73 immunosuppressive pathway unleash immune responses in combination cancer therapies

…, M Giraudon-Paoli, S Augier, A Docquier, L Gros… - Cell reports, 2019 - cell.com
Immune checkpoint inhibitors have revolutionized cancer treatment. However, many cancers
are resistant to ICIs, and the targeting of additional inhibitory signals is crucial for limiting …

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective …

…, F Guilhot, F Huguet, F Nicolini, L Legros… - The lancet …, 2010 - thelancet.com
Background Imatinib treatment significantly improves survival in patients with chronic myeloid
leukaemia (CML), but little is known about whether treatment can safely be discontinued in …

Living with television: The violence profile

G Gerbner, L Gross - The Fear of Crime, 2017 - taylorfrancis.com
… Douglass Cater and Stephen Strickland wrote a book on the report and argued for “ongoing
research capable of undergirding large public policy investigations” (l,p.l33). And, finally, a …

The major human AP endonuclease (Ape1) is involved in the nucleotide incision repair pathway

L Gros, AA Ishchenko, H Ide, RH Elder… - Nucleic acids …, 2004 - academic.oup.com
In nucleotide incision repair (NIR), an endonuclease nicks oxidatively damaged DNA in a
DNA glycosylase‐independent manner, providing the correct ends for DNA synthesis coupled …